XLV Diagnostics (Canada)

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2015 · 206 citations

Medicine, Dermatology, Immunology +11

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 193 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

Kim Papp, Yves Poulin, Robert Bissonnette et al. · Journal of the American Academy of Dermatology · 2010 · 100 citations

Medicine, Dermatology, Pharmacotherapy +4

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · British Journal of Dermatology · 2017 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +10